19 unchanged sentences
Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
−Removed: Table of Content s
Other Information.
7 unchanged sentences
Robert Abel , Executive Vice President, Chief Scientific Officer, Platform
−Removed: ( November 26, 2024 )
−Removed: Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
−Removed: Until December 31, 2025 , or such earlier date upon which all transactions are completed or expire without execution
+Added: Adoption ( November 25, 2025 )
+Added: Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares Sale Until February 6, 2027 , or such earlier date upon which all transactions are completed or expire without execution
Up to 108,746 shares
Karen Akinsanya , President of R&D, Therapeutics
−Removed: ( December 17, 2024 )
−Removed: Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
−Removed: Until December 31, 2025 , or such earlier date upon which all transactions are completed or expire without execution
+Added: ( November 11, 2025 )
+Added: Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares Sale Until December 31, 2026 , or such earlier date upon which all transactions are completed or expire without execution
Up to 114,455 shares
1 unchanged sentence
Not Applicable.
−Removed: Table of Content s
Directors, Executive Officers and Corporate Governance.
12 unchanged sentences
The information required by this Item 14 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2026 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2025 pursuant to General Instruction G(3) of Form 10-K.
−Removed: Table of Content s
Exhibits and Financial Statement Schedules.
37 unchanged sentences
10-Q 001-39206 10.2 11/12/2020
−Removed: Table of Content s
10.7+ Form of Restricted Stock Unit Agreement for Non-U.S.
3 unchanged sentences
001-39206 10.4 7/31/2024
−Removed: 10.9+ Fifth Amended and Restated Director Compensation Policy
+Added: 10.9+ Seventh Amended and Restated Director Compensation Policy
10-Q 001-39206 10.1 8/6/2025
5 unchanged sentences
S-1 333-235890 10.1 1/10/2020
+Added: 10.13+ Employment Agreement, dated May 16, 2025, by and between Schrödinger, Inc.
+Added: and Richie Jain
+Added: 001-39206 10.1 5/20/2025
10.14+ Employment Agreement, dated August 16, 2022, by and between the Registrant and Geoffrey Porges
8-K 001-39206 10.1 8/18/2022
+Added: Separation and Release of Claims Agreement, dated as of September 5, 2025, by and between the Registrant and Geoffrey Porges
+Added: 8-K 001-39206 10.1 9/8/2025
Employment Agreement, dated March 17, 2003, by and between the Registrant and Jenny Herman
8 unchanged sentences
S-1 333-235890 10.19 1/10/2020
+Added: E mployment Agreement, dated May 9, 2025, by and between the R egistrant and Mannix Aklian
Employment Agreement, dated July 28, 2023, by and between the Registrant and Margaret Dugan
−Removed: 001-39206 10.19 2/28/2024
+Added: 10-K 001-39206 10.19 2/28/2024
+Added: C onsultin g Agreement , dated Dec ember 1, 2025, by and between the Registrant and Dugan Consulting, LLC
Consultant Agreement, dated July 1, 1999, between the Registrant and Richard A.
Friesner, as amended
−Removed: 10-Q 001-39206 10.1 7/31/2024
10.25+ Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors
14 unchanged sentences
S-1 333-235890 10.25 1/10/2020
−Removed: Table of Content s
Agreement, dated as of September 2001, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC, as amended
15 unchanged sentences
10.41+ 2021 Inducement Equity Incentive Plan, as amended
−Removed: 10-Q 001-39206 10.4 11/3/2022
+Added: 333-287037 99.1 5/7/2025
10.42+ Nonstatutory Stock Option Agreement under 2021 Inducement Equity Incentive Plan
24 unchanged sentences
10-Q 001-39206 10.7 8/4/2022
−Removed: 10.47+ Amended and Restated Sales Agreement, dated as of February 28, 2024, by and between Schrödinger, Inc.
−Removed: and Leerink Partners LLC.
+Added: 10.51+ Amended and Restated Sales Agreement, dated as of February 28, 2024, by and between the Registrant and Leerink Partners LLC.
001-39206 1.1 2/29/2024
−Removed: Table of Content s
−Removed: R esearch Collaboration and License Agreement , dated as of November 11, 2024 , by and between Schrödinger , Inc.
−Removed: and Novartis Pharma AG
+Added: Research Collaboration and License Agreement, dated as of November 11, 2024, by and between the Registrant and Novartis Pharma AG
+Added: 001-39206 10.48 2/26/2025
19.1 Schrödinger, Inc.
Global Insider Trading Policy
+Added: 001-39206 19.1 2/26/2025
21.1 Subsidiaries of the Registrant
20 unchanged sentences
+ Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of the Instructions to the Annual Report on Form 10-K.
−Removed: Table of Content s
Form 10-K Summary
−Removed: Table of Content s
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized .
4 unchanged sentences
President and Chief Executive Officer
−Removed: Table of Content s
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
3 unchanged sentences
(Principal Executive Officer)
−Removed: /s/ Geoffrey Porges, MBBS Executive Vice President and Chief Financial Officer February 26, 2025
−Removed: Geoffrey Porges (Principal Financial Officer)
−Removed: /s/ Jenny Herman Senior Vice President, Finance and Corporate Controller February 26, 2025
+Added: /s/ Richie Jain
+Added: Executive Vice President and Chief Financial Officer February 25, 2026
+Added: (Principal Financial Officer)
+Added: /s/ Jenny Herman Senior Vice President, Chief Accounting Officer
+Added: February 25, 2026
Jenny Herman (Principal Accounting Officer)
9 unchanged sentences
Rosana Kapeller-Libermann, M.D., Ph.D.
+Added: /s/ Bridget van Kralingen
+Added: February 25, 2026
+Added: Bridget van Kralingen
/s/ Arun Oberoi Director February 25, 2026
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.